Account
Case Studies
26.04.2023
Optimising a phase III trial design

Our client wanted to organise an advisory board to seek guidance from a range of stakeholders within...

Read more
News
25.04.2023
PMA Insights: Week 17

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Case Studies
21.04.2023
Securing the optimum price launch price

Our client sought our expertise to support them in the development and submission of the optimum pri...

Read more
Articles
20.04.2023
EU HTA and what it means for manufacturers

Oncology products, advanced therapy medicinal products (ATMPs) and medical devices are entering the ...

Read more
Articles
13.04.2023
What are Joint Scientific Consultations and why th...

We explore joint scientific consultations; what they mean and why they are important to manufacturer...

Read more
Articles
03.04.2023
What is the joint clinical assessment and what doe...

We explore what the joint clinical assessment (JCA) is, its process and what future developments may...

Read more
News
30.03.2023
PMA Insights: Week 13 SPECIAL EDITION – Worl...

We summarise the World EPA Congress 2023 including plenary sessions on EU HTA, market archetypes, he...

Read more
Insider Insights
14.03.2023
Newly agreed Windsor Framework carries significant...

Windsor Framework replaces the Northern Ireland protocol to address issues and provide significant c...

Read more
Insider Insights
09.03.2023
What has occurred in the past year in the Swedish ...

TLV unveils annual report, offering insights into trends and projects that have dominated the past y...

Read more
Insider Insights
09.03.2023
NICE issues conditional recommendation for digital...

NICE conditionally recommends eight digitally enabled therapies to treat depression and anxiety in a...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.